Physician profile
Anson J Smith
NPI 1629044425
$18,403.88
in general payments reported to CMS, 2019-2025
20 companies · $3,921 in 2025
The $3,921 reported for 2025 was more than what 80% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $520 · 2021: $24.72 · 2022: $4,304 · 2023: $6,457 · 2024: $1,389 · 2025: $3,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $7,234 · Food and Beverage: $3,533 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $7,233.85 |
| Food and Beverage | $3,533.13 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,244.07 | 2019-2025 | Mitraclip, Triclip, Portico |
| Ancora Heart, INC. | $4,021.17 | 2023 | Accucinch |
| Edwards Lifesciences Corporation | $3,227.62 | 2022-2025 | Evoque, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Abiomed | $1,342.96 | 2022-2025 | Impella |
| Inari Medical, INC. | $858.25 | 2019-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $566.85 | 2019-2023 | |
| W. L. Gore & Associates, INC. | $316.79 | 2022-2025 | Gore Cardioform Septal Occluder |
| Cardiac Dimensions, INC. | $222.52 | 2022-2023 | |
| Shockwave Medical, INC | $134.43 | 2025 | |
| Teleflex LLC | $98.04 | 2023 | Guideliner |
| Amgen INC. | $87.21 | 2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $62.96 | 2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $47.88 | 2025 | |
| Heartflow, INC. | $45.73 | 2023 | Ffrct |
| Livanova USA, INC. | $39.59 | 2025 | Tandemheart |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $25.45 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.56 | 2025 | Jardiance |
| Cardiva Medical, INC. | $23.03 | 2023 | Cardiva Vascade 6/7f Vcs |
| Pfizer INC. | $14.77 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anson Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.